ABBV vs ASMB

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

ASMB's Advanced Deterministic Scorecard reveals severe financial health concerns: a Piotroski F-Score of 0/9 indicates extreme operational weakness, and the absence of an Altman Z-Score raises distress risk concerns. Despite this, the company exhibits strong revenue growth (57.6% YoY) and improving earnings surprises in recent quarters, suggesting potential operational turnaround. However, negative profitability metrics—such as a -103.65% profit margin and negative ROE—highlight persistent losses. The stock trades at a premium valuation (Price/Sales of 11.96) with no dividend, reflecting high growth expectations rather than intrinsic value. Analysts maintain a target price of $47.75, implying upside, but consensus is weak with only four analysts.